| P2093 | author name string | Gaosi Xu | |
| | Pingping Yang | |
| | Bufan Xiao | |
| | Honghong Zou | |
| P2860 | cites work | Heparanase mediates cell adhesion independent of its enzymatic activity | Q24303492 |
| | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q28131636 |
| | Combination of direct and indirect evidence in mixed treatment comparisons | Q29619499 |
| | Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review | Q33378916 |
| | Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis | Q33381524 |
| | Renoprotection: one or many therapies? | Q34190636 |
| | Current therapy for IgA nephropathy | Q34214875 |
| | Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis | Q34418531 |
| | The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification | Q34658768 |
| | Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy | Q35014833 |
| | Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy | Q35107938 |
| | Management of glomerular proteinuria: a commentary | Q35593193 |
| | Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study | Q36003136 |
| | Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 |
| | IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy | Q36456627 |
| | The IgA nephropathy treatment dilemma | Q36461600 |
| | Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin | Q37069971 |
| | Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate | Q37692361 |
| | The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient | Q38034908 |
| | IgA nephropathy: molecular mechanisms of the disease | Q38054796 |
| | Pathology of IgA nephropathy | Q38214812 |
| | Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial | Q38372995 |
| | Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial | Q38737028 |
| | Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses | Q39735046 |
| | Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy | Q40697919 |
| | Intensive Supportive Care plus Immunosuppression in IgA Nephropathy | Q40885799 |
| | Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: molecular clues for its activity in nephropathy. | Q41394075 |
| | The response of the Oxford classification to steroid in IgA nephropathy: a systematic review and meta-analysis | Q41708788 |
| | Tonsillectomy for IgA nephropathy: a meta-analysis | Q41759863 |
| | Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial | Q44735204 |
| | IgA subclass switch recombination in human mucosal and systemic immune compartments. | Q50880804 |
| | Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. | Q51131449 |
| | IgA nephropathy | Q86974851 |
| P433 | issue | 4 | |
| P304 | page(s) | 794-803 | |
| P577 | publication date | 2018-03-16 | |
| P1433 | published in | KI reports | Q27727507 |
| P1476 | title | Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials | |
| P478 | volume | 3 | |